uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted June 26, 2024

FDA Warns Consumers Not to Use Infla-650 Due to Undeclared Drugs

On June 20, 2024, the FDA warned consumers not to purchase or use Infla-650 after FDA laboratory analysis found them to contain acetaminophen, diclofenac, and phenylbutazone.

(See ConsumerLab's Joint Health Supplements Review for tests of products promoted for joints.)

Acetaminophen is an over-the-counter (OTC) pain reliever that can cause a rare, but potentially fatal skin reaction, and, in large doses, liver damage. Diclofenac is a prescription non-steroidal anti-inflammatory drug (NSAID) that can cause serious cardiovascular events such as heart attack or stroke, as well as bleeding, ulceration, and fatal tears of the stomach and intestines, or liver toxicity.

Phenylbutazone is a non-steroidal anti-inflammatory drug (NSAID) that was discontinued for human use in the United States due to the risk of serious and life-threatening injuries, including bone marrow toxicity. People with anemia, a low white or red blood cell count, or decreased blood platelets may be at a greater risk of death or serious injury.

Infla-650 capsules (see product photos) are promoted as an herbal dietary supplement for pain and sold on various websites, including, and potentially in some retail stores. The product’s herbal ingredients listed include ashwagandha, fenugreek seed, shilajit, and more.

Consumers and healthcare providers can report any adverse reactions to the FDA’s MedWatch Voluntary Reporting Program.

For more information, use the link below.

Infla-650 contains hidden drug ingredients

See related recalls and warnings:

FDA Warns Consumers Not to Use Tapee Tea

Toxic Herb Found In Weight Supplements

FDA Warns Consumers of Supplement Containing Prescription Anti-Inflammatory Drug

FDA Warns Consumers Not to Use Ossos-Sans Supplement for Joints

Drug Found in Umary Supplement